{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T04:13:39Z","timestamp":1784434419985,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astellas"},{"name":"CUASF Early investigator Research Scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Treatment intensification with androgen receptor pathway inhibitors (ARPIs) and\/or docetaxel in addition to androgen deprivation therapy (ADT) improves survival for men with metastatic hormone-sensitive prostate cancer (mHSPC), yet real-world uptake has historically been low. We conducted a population-based retrospective cohort study of Ontario men aged \u226566 years diagnosed with de novo mHSPC between 2014 and 2022 using linked administrative health data, defining treatment intensification as initiation of an ARPI and\/or docetaxel with ADT within six months of diagnosis. Quarterly intensification rates were modeled using autoregressive integrated moving average (ARIMA) time-series methods with nonlinear trend specifications, and competing models were compared using information criteria, out-of-sample hold-out forecast accuracy, and long-horizon extrapolation behaviour to project uptake through 2030. Among 6099 men, 24% received treatment intensification, with quarterly intensification rates increasing from 3% in 2014 to 56% in 2022. A restricted cubic spline ARIMA model (ARIMA(1,0,1) + RCS3) was selected as the primary base-case forecast because it showed superior out-of-sample hold-out accuracy and more tempered long-horizon extrapolation. The cubic specification was retained as an upper-bound scenario, reflecting the possibility of continued aggressive momentum in treatment adoption. Both specifications captured a marked inflection after 2020 that temporally coincided with guideline updates and funding expansions. Near-term base-case projections (through 2026) suggest continued growth in intensification toward 80\u201385%, with the upper-bound scenario approaching saturation more quickly. Projections beyond 2026 are exploratory and presented for methodological completeness, given the eight-year horizon relative to a nine-year observation window and the widening prediction intervals at extended horizons. Despite substantial growth over time, treatment intensification remains incomplete in routine practice. These findings are temporally consistent with the impact of policy and funding changes on the adoption of evidence-based therapy and underscore the need for ongoing implementation efforts to address persistent clinical and system-level barriers to equitable access.<\/jats:p>","DOI":"10.3390\/curroncol33050276","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:35:43Z","timestamp":1778528143000},"page":"276","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis"],"prefix":"10.3390","volume":"33","author":[{"given":"Ealia","family":"Khosh Kish","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erind","family":"Dvorani","sequence":"additional","affiliation":[{"name":"ICES, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[{"name":"ICES, Toronto, ON M4N 3M5, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Wilton","sequence":"additional","affiliation":[{"name":"ICES, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satkunasivam","sequence":"additional","affiliation":[{"name":"Department of Urology, Houston Methodist Hospital, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatereh","family":"Aminoltejari","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-6079","authenticated-orcid":false,"given":"Amanda","family":"Hird","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Urology, Department of Surgery, Sunnybrook Health Sciences, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Berscheid","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-3346","authenticated-orcid":false,"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radiation Oncology and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-5541","authenticated-orcid":false,"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 1C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-2292","authenticated-orcid":false,"given":"Di Maria","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Gotto","sequence":"additional","affiliation":[{"name":"Departments of Surgery and Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Shayegan","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, St. Joseph\u2019s Healthcare Hamilton, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Breau","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1G 5Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan A.","family":"Lalani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-8792","authenticated-orcid":false,"given":"David-Dan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-4026","authenticated-orcid":false,"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Division of Urology, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1002\/cncr.70070","article-title":"Association of Patient and Physician Characteristics with Androgen-Deprivation-Therapy Intensification in Patients with de Novo Hormone-Sensitive Metastatic Prostate Cancer: A Population-Based Study","volume":"131","author":"Nguyen","year":"2025","journal-title":"Cancer"},{"key":"ref_2","first-page":"E25","article-title":"Practice Patterns and Predictors of Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer","volume":"19","author":"Gotto","year":"2025","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e71176","DOI":"10.1002\/cam4.71176","article-title":"Treatment Landscape for Older Men with Metastatic Hormone-Sensitive Prostate Cancer in the United States","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.3390\/curroncol30090591","article-title":"A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)","volume":"30","author":"Karim","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/OP-24-00690","article-title":"Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States from 2017 to 2023","volume":"21","author":"Raval","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-024-05388-1","article-title":"Androgen Receptor Pathway Inhibitors vs. Docetaxel Chemotherapy for Metastatic Hormone-Sensitive and First-Line Castration Resistant Prostate Cancer","volume":"43","author":"NWenzel","year":"2024","journal-title":"World J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"pkab082","DOI":"10.1093\/jncics\/pkab082","article-title":"Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer","volume":"5","author":"Wallis","year":"2021","journal-title":"JNCI Cancer Spectr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e390166","DOI":"10.1200\/EDBK_390166","article-title":"Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment","volume":"43","author":"Hamid","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update","volume":"41","author":"Virgo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/14796694.2025.2479374","article-title":"Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Study in Alberta, Canada","volume":"21","author":"Yip","year":"2025","journal-title":"Future Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jnci\/djae302","article-title":"The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities","volume":"117","author":"Hammarlund","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nguyen, D.-D., Satkunasivam, R., Aminoltejari, K., Hird, A., Roy, S., Morgan, S.C., Shayegan, B., Kulkarni, G.S., Trinh, Q.-D., and Rosella, L.C. (2026). Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada. JCO Oncol. Pract.","DOI":"10.1200\/OP-25-00766"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E1416","DOI":"10.1503\/cmaj.212076","article-title":"Ensuring Equitable Access to Cancer Care for Black Patients in Canada","volume":"194","author":"Ezeife","year":"2022","journal-title":"CMAJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41585-024-00948-x","article-title":"Racial Disparities in Prostate Cancer in the UK and the USA: Similarities, Differences and Steps Forwards","volume":"22","author":"Dee","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/jnci\/djac137","article-title":"Addressing Social Determinants of Health: Now Is the Time","volume":"114","author":"Bona","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2448707","DOI":"10.1001\/jamanetworkopen.2024.48707","article-title":"Physician Reasons for or Against Treatment Intensification in Patients with Metastatic Prostate Cancer","volume":"7","author":"Agarwal","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2535728","DOI":"10.1001\/jamanetworkopen.2025.35728","article-title":"Barriers and Facilitators of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer","volume":"8","author":"Loeb","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41391-022-00556-z","article-title":"Role of Multidisciplinary Team Meetings in Implementation of Chemohormonal Therapy in Metastatic Prostate Cancer in Daily Practice","volume":"26","author":"Creemers","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jnci\/djaf017","article-title":"Frailty and Outcomes in Adults Undergoing Systemic Anticancer Treatment: A Systematic Review and Meta-Analysis","volume":"117","author":"Pearce","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hoffman, A., and Amiel, G.E. (2023). The Impact of PSMA PET\/CT on Modern Prostate Cancer Management and Decision Making\u2014The Urological Perspective. Cancers, 15.","DOI":"10.3390\/cancers15133402"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for Primary Staging of Prostate Cancer-An Updated Overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Combes, A.D., Palma, C.A., Calopedos, R., Wen, L., Woo, H., Fulham, M., and Leslie, S. (2022). PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics, 12.","DOI":"10.3390\/diagnostics12112594"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE Guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J. Anaesth."},{"key":"ref_33","unstructured":"Box, G.E.P., and Jenkins, G.M. (1976). Time Series Analysis Forecasting and Control, Holden Day. Available online: https:\/\/www.scirp.org\/reference\/referencespapers?referenceid=1969833."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1051\/ro\/1977110201291","article-title":"The Box-Jenkins Approach to Time Series Analysis and Forecasting: Principles and Applications","volume":"11","author":"Young","year":"1977","journal-title":"RAIRO-Oper. Res."},{"key":"ref_35","first-page":"427","article-title":"Distribution of the Estimators for Autoregressive Time Series with a Unit Root","volume":"74","author":"Dickey","year":"1979","journal-title":"J. Am. Stat. Assoc."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/276\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:46:10Z","timestamp":1778561170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050276"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050276","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}